Turner NC, Swift C, Kilburn LS, Fribbens C, et al. ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor positive breast cancer: A combined analysis of the phase III SoFEA and EFECT trials. Clin Cancer Res 2020 Jun 16. pii: 1078-0432.CCR-20-0224.
PMID: 32546646